Home/Filings/4/0001415889-20-000092
4//SEC Filing

Schneiderman Daniel H 4

Accession 0001415889-20-000092

CIK 0001604191other

Filed

Jan 8, 7:00 PM ET

Accepted

Jan 9, 4:10 PM ET

Size

5.5 KB

Accession

0001415889-20-000092

Insider Transaction Report

Form 4
Period: 2020-01-02
Schneiderman Daniel H
CHIEF FINANCIAL OFFICER
Transactions
  • Award

    Options

    2020-01-02+335,006335,006 total
    Exercise: $1.03Exp: 2030-01-02Common Stock (335,006 underlying)
Footnotes (1)
  • [F1]Options granted in connection with the Reporting Person's appointment as Chief Financial Officer of the Issuer. The options will vest in three equal annual installments commencing on the first anniversary of the grant date, becoming fully vested on January 2, 2023.

Issuer

AzurRx BioPharma, Inc.

CIK 0001604191

Entity typeother

Related Parties

1
  • filerCIK 0001565536

Filing Metadata

Form type
4
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 4:10 PM ET
Size
5.5 KB